Tacrolimus prolonged release in kidney transplantation

Expert Review of Clinical Immunology

Volumn 5, Issue 2, 2009, Pages 127-133

  Krämer, Bernhard K ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Advagraf ; Graft survival; Immunosuppression; Kidney transplantation; Nonadherence; Tacrolimus prolonged release

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; STEROID; TACROLIMUS;

ADVERSE OUTCOME; ALOPECIA; AREA UNDER THE CURVE; ARTERIOVENOUS FISTULA; BEDTIME DOSAGE; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MICROEMULSION; MORNING DOSAGE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; ORTHOSTATIC HYPERTENSION; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SINUSITIS; SUSTAINED RELEASE FORMULATION; SUSTAINED RELEASE PREPARATION; THROMBOSIS; TREATMENT OUTCOME; TREMOR; VISUAL ACUITY;

EID: 77649134000     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.5.2.127     Document Type: Review

References (30)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am. J. Transplant. 4(8), 1289-1295 (2004).
2. Denhaerynck K, Dobbels F, Cleemput I et al. Prevalence, consequences, and determinants of non-adherence in adult renal transplant patients: a literature review. Transpl. Int. 18(10), 1121-1133 (2005).
3. Butler JA, RoDerick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of non-adherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 77(5), 769-776 (2004).
4. Vasquez EM, Tanzi M, Benedetti E, Pollak R. Medication noncompliance after kidney transplantation. Am. J. Health Syst. Pharm. 60(3), 266-269 (2003).
5. Dew MA, Dimartini AF, De Vito DA et al. Rates and risk factors for non-adherence to the medical regimen after adult solid organ transplantation. Transplantation 83(7), 858-873 (2007).
6. Siegal B, Greenstein S. Compliance and noncompliance in kidney transplant patients: cues for transplant coordinators. J. Transpl. Coord. 9(2), 104-108 (1999).
7. Weng FL, Israni AK, Joffe MM et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J. Am. Soc. Nephrol. 16(6), 1839-1848 (2005).
8. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 6(5), 592-599 (1984).
9. Guillausseau PJ. Impact of compliance with oral antihyperglycemic agents on health outcomes in Type 2 diabetes mellitus: a focus on frequency of administration. Treat. Endocrinol. 4(3), 167-175 (2005).
10. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther. 24, 302-316 (2002).
11. Kardas P. Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial. Vasc. Health Risk Manag. 3(2), 235-242 (2007).
12. Stang P, Suppapanaya N, Hogue SL, Park D, Rigney U. Persistence with once-daily versus twice-daily bupropion for the treatment of depression in a large managed-care population. Am. J. Ther. 14(3), 241-246 (2007).
13. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 63(12), 1247-1297 (2003).
14. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin. Pharmacol. Ther. 75(5), 434-447 (2004).
15. Undre NA, Van Hooff J, Christiaans M et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant. Proc. 31(1-2), 296-298 (1999).
16. Undre NA, Stevenson PJ. Pharmacokinetics of tacrolimus in heart transplantation. Transplant. Proc. 34(5), 1836-1838 (2002).
17. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62(7), 920-926 (1996).
18. Venkataramanan R, Shaw LM, Sarkozi L et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J. Clin. Pharmacol. 41(5), 542-551 (2001). (Pubitemid 32381872)
19. Chisholm MA, Middleton MD. Modifiedrelease tacrolimus. Ann. Pharmacother. 40(2), 270-275 (2006).
20. Cross SA, Perry CM. Tacrolimus oncedaily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs 67(13), 1931-1943 (2007).
21. Undre NA; for the Tacrolimus Modified Release Kidney Study Group. Use of a once daily modified release tacrolimus regimen in de novo kidney transplant recipients. Am. J. Transplant. 5(Suppl. 11), 190 (2005) (Abstract 132).
22. Wlodarcyzk Z, Squifflet J-P, Ostrowski M et al. Two-year follow-up of a once-daily modified release tacrolimus regimen in de novo kidney transplant recipients. Transpl. Int. 20(Suppl. 2), 27 (2007) (Abstract O093).
23. Alloway R, Steinberg S, Khalil K et al. Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen. Transplant. Proc. 37(2), 867-870 (2005). (Pubitemid 40590728)
24. Macphee I, FreDericks S, Tai T et al. Tacrolimus pharmacogenetics, polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74(11), 1486-1489 (2002).
25. Hesselink DA, Van Schaik RH, Van Der Heiden IP et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003).
26. Alloway R, Steinberg S, Khalil K et al. Two years postconversion from a Prografbased regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 83(12), 1648-1651 (2007). (Pubitemid 46987920)
27. Van Hooff JP, Van Der Walt I, Kallmeyer J, Miller D, Dawood S, Moosa M. Two year follow-up of stable kidney transplant recipients converted from twice daily Prograf to once daily modified release tacrolimus. Transpl. Int. 20(Suppl. 2), 129 (2007) (Abstract P141).
28. Silva HT, Jr, Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am. J. Transplant. 7(3), 595-608 (2007).
29. Yang H; for the Tacrolimus Extended Release De Novo Kidney Study Group. A Phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf® (cyclosporine)/MMF in de novo kidney transplant recipients: 2 year results. Am. J. Transplant. 7(Suppl. 2), 183 (2007) (Abstract 144).
30. Banas B, Krämer B, Charpentier B et al. Tacrolimus once-daily prolonged release versus tacrolimus twice-daily in combination with MMF and steroids: a Phase III multicentre renal study. Transplantation 86(Suppl. 2), 540 (2008) (Abstract 1628).